Phase 3 KEYNOTE-B15 data demonstrate that perioperative enfortumab vedotin and pembrolizumab significantly improve EFS, OS, and pCR compared with standard chemotherapy.

Phase 4 COMPARE trial data show Nuvaxovid was associated with lower reactogenicity and fewer daily activity disruptions than mNEXSPIKE.

Based on positive phase 3 trial results, a New Drug Application will be submitted to the Food and Drug Administration for daraxonrasib.

Topline data for the once-daily PKR activator etavopivat demonstrate a 27% reduction in vaso-occlusive crises and a robust hematologic response in patients with SCD.

From 2015 to 2023, there was a decrease in the number of US patients prescribed long-term opioid therapy, according to a study published online April 8 in the J ...

Sixty-eight percent of studies exceeded benchmark of about 25% total weight loss attributable to reduction in muscle-based indices.

Human-generated notes received higher overall modified Physician Documentation Quality Instrument scores than AI-generated notes across all 5 clinical cases. HealthDay News — Notes generated by ...

Recommendations say clinicians should use biennial mammography for breast cancer screening in asymptomatic, average-risk women aged 50 to 74 years ...

The US Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies. Peptides are small chains of amino acids ...

Nearly half of responses from five popular chatbots were problematic, particularly about stem cells, athletic performance, and nutrition, ...

Tozorakimab met its primary endpoint in the MIRANDA trial, demonstrating the potential of IL-33 inhibition to reduce exacerbations and improve outcomes for a broad population of COPD patients. Topline ...

Social media posts about glucagon-like peptide-1 receptor agonists may identify patient concerns not captured in clinical trials, according to a study published ...